ACMT Highlights Tox-in-Ten: Episode 51
-
Register
- Non-member - Tier I - Free!
- Non-member - Tier II - Free!
- Non-member - Tier III - Free!
- Non-member - Tier IV - Free!
- Member - Tier I - Free!
- Member - Tier II - Free!
- Member - Tier III - Free!
- Member - Tier IV - Free!
F(ab)2 Antivenom and the Management of Snakebite
In this episode, Dr. Gillian Beauchamp sits down with Dr. Meghan Spyres to discuss the evolution of antivenom treatment of North American Pit Viper envenomation with specific discussion of the differences between Fab (CroFab) and F(ab)2 (ANAVIP) antivenom.
Key:
ACMT members Gillian Beauchamp, MD, and Elizabeth (Elissa) Moore, DO deliver evidence-based medical toxicology core content and trending topics in easily digestible bites. Visit toxinten.com and follow on Twitter @toxinten.
Gillian Beauchamp, MD, FACMT, FASAM (Moderator)
Vice Chair, Education & Community Engagement
Lehigh Valley Health Network, USF Morsani College of Medicine, Jefferson Health
Gillian Beauchamp, MD, is Vice Chair for Education and Community Engagement in the Lehigh Valley Health Network Department of Emergency and Hospital Medicine & Division of Medical Toxicology. She is an Associate Professor at USF Morsani College of Medicine, and Adjunct Clinical Associate Professor at Jefferson University. She is board certified in Emergency Medicine, Medical Toxicology and Addiction Medicine. She is an Editorial board member for Toxicology Communications and a Reviews Section Editor and Editorial board member for the Journal of Medical Toxicology; and is co-host for the Tox in Ten: ACMT Highlights podcast.
Stephanie Weiss, MD, PhD
Staff Clinician, Translational Addiction Medicine Branch
National Institute on Drug Abuse
Dr. Stephanie Weiss is the Staff Research Physician serving the Translational Addiction Medicine Branch of the National Institute on Drug Abuse’s Intramural Research Program. After earning a Ph.D. in pharmaceutical chemistry, Dr. Weiss received her medical degree in 2011. She is board certified in emergency medicine, addiction medicine, and medical toxicology and was selected to participate in the Boston University Research in Addiction Medicine Scholars Program prior to joining NIDA. Dr. Weiss is responsible for providing optimal, safe, and ethical care to study participants and clinical support toward the TAMB mission conducting inpatient and outpatient proof-of-concept human laboratory studies. Her research interests include novel psychoactive substances, medication misuse, and improving interpretation of urine drug testing.